Treatment decisions for localized prostate cancer: asking men what's important
- PMID: 11089712
- PMCID: PMC1495597
- DOI: 10.1046/j.1525-1497.2000.90842.x
Treatment decisions for localized prostate cancer: asking men what's important
Abstract
Objective: To identify what factors men consider important when choosing treatment for prostate cancer, and to assess why men reject watchful waiting as a treatment option.
Participants: One hundred two consecutive men with newly diagnosed localized prostate cancer identified from hospital and community-based urology practice groups.
Measurements: Patients were asked open-ended questions about likes and dislikes of all treatments considered, how they chose their treatment, and reasons for rejecting watchful waiting. The interviews were conducted in person, after the men had made a treatment decision but before they received the treatment.
Main results: The most common reasons for liking a treatment were removal of tumor for radical prostatectomy (RP) (n = 15), evidence for external beam radiation (EBRT) (n = 6), and short duration of therapy for brachytherapy (seeds) (n = 25). The most frequently cited dislikes were high risk of incontinence for RP (n = 46), long duration of therapy for EBRT (n = 29), and lack of evidence for seeds (n = 16). Only 12 men chose watchful waiting. Fear of future consequences, cited by 64% (n = 90) of men, was the most common reason to reject watchful waiting.
Conclusion: In discussing treatment options for localized prostate cancer, clinicians, including primary care providers, should recognize that patients' decisions are often based on specific beliefs regarding each therapy's intrinsic characteristics, supporting evidence, or pattern of complications. Even if patients do not recall a physician recommendation against watchful waiting, this option may not be chosen because of fear of future consequences.
Similar articles
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
-
Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy.BJU Int. 2011 Oct;108(8):1274-8. doi: 10.1111/j.1464-410X.2011.10082.x. Epub 2011 Mar 16. BJU Int. 2011. PMID: 21410634
-
Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study.BJU Int. 2002 Aug;90(3):257-64. doi: 10.1046/j.1464-410x.2002.02846.x. BJU Int. 2002. PMID: 12133062
-
Early prostate cancer--which treatment do men prefer and why?BJU Int. 2011 Jun;107(11):1762-8. doi: 10.1111/j.1464-410X.2010.09833.x. Epub 2010 Nov 17. BJU Int. 2011. PMID: 21083643
-
Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393. Semin Urol Oncol. 2002. PMID: 11828353 Review.
Cited by
-
Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.BMC Cancer. 2021 May 11;21(1):538. doi: 10.1186/s12885-021-08281-x. BMC Cancer. 2021. PMID: 33975579 Free PMC article. Clinical Trial.
-
Health related quality of life for men treated for localized prostate cancer with long-term followup.J Urol. 2010 Jun;183(6):2206-12. doi: 10.1016/j.juro.2010.02.013. J Urol. 2010. PMID: 20399462 Free PMC article.
-
Urologists' attitudes regarding information sharing with prostate cancer patients--is there a common ground for collaboration with family physicians?J Cancer Educ. 2011 Jun;26(2):315-21. doi: 10.1007/s13187-010-0171-1. J Cancer Educ. 2011. PMID: 20972846
-
Five-year nationwide follow-up study of active surveillance for prostate cancer.Eur Urol. 2015 Feb;67(2):233-8. doi: 10.1016/j.eururo.2014.06.010. Epub 2014 Jun 30. Eur Urol. 2015. PMID: 24993868 Free PMC article.
-
Family physicians' perceptions, beliefs, and attitudes regarding information sharing with prostate cancer patients throughout the course of the disease.Support Care Cancer. 2008 Aug;16(8):955-61. doi: 10.1007/s00520-007-0358-0. Epub 2007 Nov 28. Support Care Cancer. 2008. PMID: 18043950
References
-
- Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1995;48:6–29. - PubMed
-
- Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med. 1995;333:1401–5. - PubMed
-
- Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993;153:2529–37. - PubMed
-
- Perkins T. Concern grows over prostate cancer treatment options. JNCI. 1994;86:987–8. - PubMed
-
- Menon M, Parulker BG, Baker S. Should we treat localized prostate cancer. An opinion. Urology. 1995;46:607–15. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical